Cost‐effectiveness analysis of empagliflozin versus sitagliptin as <scp>second‐line</scp> therapy for treatment in patients with type 2 diabetes in the United States

Abstract

Compared with sitagliptin, empagliflozin was cost-effective (at $50 000/QALY US threshold) as a second-line treatment to metformin for T2D patients with or without CVD in the United States. Our findings lend additional support for more widespread adoption of guidelines by healthcare decision-makers for T2D treatment.